All In Biotech

Drug Trial Radar · NCT06097832

Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis

Phase 1b/2 Study of NXC-201 for the Treatment of Patients With Relapsed or Refractory AL Amyloidosis

Last checked: Nov 19, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Jun 5, 2024

Primary completion

Dec 2026

Study completion Jan 2039

Sponsor

Lead sponsor
Nexcella Inc.Industry
Sponsor type
Industry
Collaborators
Immix Biopharma, Inc.
First posted
Oct 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 120 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Open-label Phase 1b Dose Escalation/Dose Expansion study exploring the safety and efficacy of NXC-201 in patients with relapsed or refractory light chain amyloidosis (AL).

Conditions

  • Light Chain (AL) Amyloidosis

Interventions

  • NXC-201 CAR-TBiological

    NXC-201 (formerly HBI0101) CAR-T is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The NXC-201 CAR-T is provided fresh without cryopreservation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Related Adverse EventsTime frame: 24 months
  2. Number of Participants with Adverse Events by Severity as Assessed by CTCAE v5.0Time frame: 24 months
  3. To confirm the maximum tolerated dose (MTD)Time frame: 24 months
  4. To confirm the recommended phase 2 dose (RP2D)Time frame: 24 months

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Sutter Health Alta Bates

    Berkeley, California

  • City of Hope

    Duarte, California

  • University of California Los Angeles

    Los Angeles, California

  • University of California Davis Medical Center

    Sacramento, California

  • Stanford University

    Stanford, California

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia

  • The University of Kansas Cancer Center

    Fairway, Kansas

  • Tufts Medical Center

    Boston, Massachusetts

  • Boston University Medical Center

    Boston, Massachusetts

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan

  • Masonic Cancer Center, University of Minnesota

    Minneapolis, Minnesota

  • Washington University Siteman Cancer Center

    St Louis, Missouri

  • Memorial Sloan Kettering Comprehensive Cancer Center

    New York, New York

  • University of Cincinnati Cancer Center

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Baptist Memorial Hospital

    Memphis, Tennessee

  • Huntsman Cancer Institute at the University of Utah

    Salt Lake City, Utah

  • Swedish Cancer Institute

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.